Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

Figure 2

Gene mutation panorama of colorectal cancer patients in the immunotherapy cohort (a) and TCGA-COAD cohort (b) and the relationship between PI3K/Akt pathway mutations and clinical characteristics (c). (a) The 20 genes with the highest mutation frequencies in COAD patients in the immunotherapy cohort and their corresponding clinical characteristics are displayed. The mutation frequencies of PIK3CA, ARID1A, and PTPRS were significantly increased in the PI3K/Akt-MT group. Yellow represents cleavage site mutations, blue represents missense mutations, orange represents frame shift mutations, green represents insertion/deletion mutations, and brown represents nonsense mutations. (b) The 20 genes with the highest mutation frequencies in patients in the TCGA-COAD cohort and their corresponding clinical characteristics are displayed. With the exception of KRAS, the mutation frequencies of all other genes changed significantly. Yellow represents cleavage site mutations, blue represents missense mutations, orange represents frame shift mutations, green represents insertion/deletion mutations, and brown represents nonsense mutations. (c) Relationship between PI3K/Akt pathway mutations and clinical characteristics such as age, sex, and sample type differences in the immunotherapy cohort (; ; ; ; Fisher’s exact test).

(a)

(b)

(c)